First multicentre experience of SABR for lymph node and liver oligometastatic disease on the unity MR-Linac. Tech Innov Patient Support Radiat Oncol 2022 Jun;22:50-54
Date
05/20/2022Pubmed ID
35586786Pubmed Central ID
PMC9108982DOI
10.1016/j.tipsro.2022.04.005Scopus ID
2-s2.0-85129945098 (requires institutional sign-in at Scopus site) 6 CitationsAbstract
The treatment of oligometastatic disease using MR guidance is an evolving field. Since August 2018 patients are treated on a 1.5 Tesla MR-Linac (MRL). We present current workflows and practice standards from seven institutions for the initial patients treated for lymph node and liver metastases.